title: Eplerenone in patients with chronic recurring central serous chorioretinopathy.
abstract: OBJECTIVE
  To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC).
  
  
  METHODS
  In this retrospective case series, 11 patients with chronic recurring CSC were included. The main focus was to include patients who had undergone photodynamic therapy (4 patients), had undergone anti-vascular endothelial growth factor treatment (3 patients), or had several episodes of CSC in the past (4 patients) (mean age 60 years; SD 9.7, range 47-76).
  
  
  RESULTS
  Four patients (36.4%) had full resorption of neurosensory detachment under therapy of eplerenone with improvement of vision, while 4 more patients had improvement of vision despite residual edema. Eight patients (73%) had improved visual acuity (VA) at the end of eplerenone therapy, 2 patients had no change in VA, and 1 patient decreased VA. Mean time of treatment was 10.6 ± 9.9 weeks (range 3-38 weeks). All patients showed subretinal deposits, with 6 of them having hyperautofluorescent subretinal deposits.
  
  
  CONCLUSIONS
  Eplerenone represents a new treatment option for patients with CSC. Our data indicate a good response in those patients, leading to improvement of VA in 73% of patients.
authors.affiliation: VIROS-Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna - Austria.
authors.forename: Christoph
authors.initials: C
authors.lastname: Leisser
authors.affiliation: VIROS-Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna - Austria.
authors.forename: Nino
authors.initials: N
authors.lastname: Hirnschall
authors.affiliation: VIROS-Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna - Austria.
authors.forename: Christoph
authors.initials: C
authors.lastname: Hackl
authors.affiliation: 1 Medical Department, Hanusch Hospital, Vienna - Austria.
authors.forename: Pia
authors.initials: P
authors.lastname: Plasenzotti
authors.affiliation: VIROS-Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna - Austria.|Moorfields Eye Hospital NHS Foundation Trust, London - UK.
authors.forename: Oliver
authors.initials: O
authors.lastname: Findl
mesh_terms: D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D000077545:Eplerenone; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D010778:Photochemotherapy; D012008:Recurrence; D012189:Retrospective Studies; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone